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We have previously demonstrated that a human immunodeficiency virus (HIV) chimeric Gag protein containing a partial replacement of
the matrix domain by the viral protease domain (PR) could undergo autoprocessing with no virus particle production [J. Virol. 74 (2000)
3418]. To further analyze the effects of repositioned PR on virus particle production and Gag-Pol incorporation, we introduced the chimeric
PR construct into a PR-negative Gag-Pol expression plasmid and coexpressed the resultant construct with a Pr55gag expression plasmid
(pGAG) in 293T cells. Analysis indicated that the chimeric PR was similar to native PR in that both could prevent virus particle production in
cotransfections with an equivalent amount of pGAG plasmid DNA, suggesting an efficient trans processing of Pr55gag by the chimeric PR. In
cotransfections with the pGAG at a DNA ratio of 1:10 to 1:20, which resembles the normal intracellular expression ratio of Gag-Pol to Gag,
Gag-Pol carrying the PR in the Gag coding region could undergo autoprocessing in cells and was incorporated into virus particles at a level
about 20–40% of that of wild-type Gag-Pol. However, the incorporated chimeric Gag-Pol was unable to autocleave and unable to process the
Gag particles properly, as mature particle-associated reverse transcriptase (RT) and p24gag proteins were barely detected. Our data strongly
suggest that positioning an active HIV PR in the matrix region significantly affects the PR-mediated virus particle maturation.
D 2003 Published by Elsevier Inc.Keywords: Gag-Pol; HIV PR; Autoprocessing
Introduction 1988). The sequence of HIV pol partially overlaps with theRetroviral gag genes encode the structural protein Gag,
which can self-assemble into virus-like particles (Wills and
Craven, 1991). The human immunodeficiency virus (HIV)
Gag protein is synthesized initially as a polyprotein,
Pr55gag. During or after virus budding from the cell mem-
brane, the Pr55gag is cleaved by the pol-encoded protease
(PR) into four major products: matrix-associated protein
(MA; p17), capsid protein (CA; p24), nucleocapsid (NC;
p7), and the carboxy-terminal p6 domain (Henderson et al.,
1992; Kaplan et al., 1994; Leis et al., 1988; Mervis et al.,0042-6822/$ - see front matter D 2003 Published by Elsevier Inc.
doi:10.1016/j.virol.2003.08.043
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E-mail address: chintien@ym.edu.tw (C.-T. Wang).gag coding sequence. During translation of Gag, a-1 ribo-
somal frameshift event occurs at a frequency of about 5–
10%, resulting in translation of Pol as a Pr160gag-pol poly-
protein (Jacks et al., 1988). Within the Gag-Pol fusion
protein, the p6 is truncated and replaced by a transframe
domain referred to as p6* (Partin et al., 1990). A number of
studies have suggested that p6* may play a role in the
regulation of PR activation (Partin et al., 1991; Tessmer and
Krausslich, 1998; Zybarth et al., 1994).
The process of PR activation has not been completely
elucidated yet. It is thought that the PR is activated via
dimerization, which is promoted by Gag and Gag-Pol inter-
actions during virus assembly. The activated PR dimer first
cleaves itself out of the Gag-Pol polyprotein and then cleaves
the Gag andGag-Pol precursors. Proteolytic processing of the
Gag-Pol polyprotein gives rise to reverse transcriptase (RT)
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Proteolytic processing of the Gag precursor is essential for
virus infectivity, but is not required for virus assembly and
budding (Gottlinger et al., 1989; Kohl et al., 1988; Peng et al.,
1989). However, the expression ratio of Gag versus Gag-Pol
appears to be critical for virus assembly and budding since
artificial overexpression of Gag-Pol abolishes virus budding,
presumably due to premature processing of Gag precursors
by the overexpressed PR (Arrigo and Huffman, 1995; Bur-
stein et al., 1991; Hill et al., 2001; Krausslich, 1991; Park and
Morrow, 1991; Rose et al., 1995; Shehu-Xhilaga et al., 2001;
Xiang et al., 1997).
Expression of gag alone, without pol and env, is
sufficient for assembly and budding of virus-like particles
(Freed, 1998; Hunter, 1994; Wills and Craven, 1991). Also,
a number of studies have demonstrated that retroviral gag
mutants containing a foreign protein-coding sequence in
place of the gag sequence which is dispensable for particle
formation could still direct assembly and budding of
chimeric virus-like particles (Bennett et al., 1993; Weldon
and Wills, 1993; Zhang et al., 1998). We have demonstrat-
ed previously that replacement of most of the HIV MA
codons with an inactivated HIV PR has little effect on
assembly and budding of virus particles (Wang et al.,
2000). Additionally, the chimeric particles were proteolyt-
ically processed and contained appreciable RT activity
when the downstream pol region remained intact. We have
extended the previous study to examine the effects ofFig. 1. HIV-1 Gag and Gag-Pol expression vectors. Wild-type (WT) HIV Gag prot
pol encoded transframe domains p6* (hatched rectangle) and PR (protease; shaded
mutation, which was made by changing the Asp residue for proteolytic activity to A
in which the Phe residue at the C terminus of p6* has been replaced with Val (arrows
MA codons with the p6*-PR, as described in Materials and methods. Each of the mu
or into a gag-pol frameshift (FS) derivative of HIVgpt.chimeric PR on Gag processing and Gag-Pol incorporation.
Our analyses indicate that when placed in the MA, HIV PR
could cleave coexpressed Pr55gag in trans. However, the
virus-associated Gag-Pol molecules could not undergo
autoprocessing and could not process Pr55gag particles
properly. These results suggest that the function of HIV
PR in the cleavage of virus-associated Pr160gag-pol and
Pr55gag is positionally dependent.Results
HIV chimeric proteins containing a partial substitution of
the MA domain by the PR coding sequences could undergo
autoprocessing and cleave Pr55gag in trans
We have previously reported that an HIV chimera con-
taining p6*-PR in the MA region of a PR-defective HIV
mutant could autocleave efficiently (Wang et al., 2000). This
suggests that HIV PR still possesses proteolytic activity when
placed out of its native position. To further test the ability of
the chimeric PR to cleave Pr55gag particles and its effect on
the Gag-Pol incorporation, we introduced the chimeric PR
construct MA(p6*-PR) into an HIV Gag-Pol frameshift
mutant, FS, of which the pol and gag were placed in the
same reading frame, leading to expression of the Pr160gag-pol
only (Fig. 1). To observe the PR activity of the engineered
constructs in a convenient way, the downstream native PR inein domains MA (matrix), CA (capsid), NC (nucleocapsid), and p6; and the
rectangle) are indicated at the top. The ‘‘X’’ indicates a protease-defective
sn. The blocking mutation at the N-terminal PR cleavage site is denoted V/P,
). Chimeric PR-expressing vectors were constructed by replacing most of the
tations was introduced individually or in combination into the HIVgpt vector,
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versa in the case of MA(p6*-D25)FS, in which the inserted
chimeric PR was inactivated while the downstream PR
remained intact. Each of the FS mutants was expressed alone
or coexpressed with a Pr55gag-expression plasmid, pGAG, in
293T cells. The effects of the chimeric PR on particle
assembly and processing were assessed by Western immu-
noblot experiments. As shown in Fig. 2, MA(p6*-PR)FSD
demonstrated an autoprocessing profile similar to that of FS
(lanes 12–13), which was used as a wild-type (wt) control.
This suggests that the HIV PR placed in the MA region was
functionally expressed. However, p24gagwas barely detectedFig. 2. Assembly and processing of HIV Gag proteins. 293T cells were
transfected or cotransfected with the plasmids indicated. For individual
transfections, 20 Ag of each plasmid DNAwas used, and for cotransfection,
10 Ag of pGAG and 1 Ag of the indicated constructs were used with the
addition of 9 Ag of pBlueScript SK. At 48 h posttransfection, cells and
supernatants were collected for protein analysis as described in Materials
and methods. Cell samples corresponding to 4% of total cell lysates, and
supernatant samples corresponding to 50% of total recovered viral pellets
were fractionated by 10% SDS-PAGE. HIV Gag proteins were probed with
an anti-p24gag monoclonal antibody. HIV Gag proteins Pr55, p41, and p24
are indicated on the left and the positions of molecular size markers (Std.)
are shown on the right.in the medium sample of MA(p6*-PR)FSD cotransfectants
(Fig. 2, lane 7). In contrast, p24gag represented the major
species in the medium sample of FS cotransfectants (lane 6).
These results suggest that the Gag-Pol encoded by MA(p6*-
PR)FSD was unable to process Pr55gag particles, possibly
due to a severe defect in particle incorporation of the encoded
Gag-Pol. Under normal circumstances, a minimum amount
of Gag-Pol is sufficient to provide enough PR activity for the
processing of Gag particles (Chiu et al., 2002). Thus, the
results showing barely detectable mature Gag in the medium
may suggest that the incorporation of Gag-Pol into virus
particles was almost totally eliminated. Alternatively, the
process of PR activation may have been blocked, or the PR
simply could not gain access to the cleavage sites. When the
PR inserted into the MA region was inactivated by a point
mutation and expressed in the context of FS, the encoded
Gag-Pol could process Pr55gag particles (lanes 8 and 17).
This suggests that the chimeric PR mutation did not com-
pletely prevent the incorporation of Gag-Pol into virus
particles, and that the native PR in the downstream pol could
functionally complement the inactivated chimeric PR to
process Gag particles.
Effects of chimeric PR expression level on virus particle
budding and processing
Because the levels of virus particle budding and virus-
associated Gag-Pol could be significantly affected by the
level of expressed PR, we evaluated the effects of the
expression level of chimeric PR on virus particle budding
and Gag-Pol incorporation. To do so, wt and mutant FS
constructs were used in cotransfections with pGAG at various
plasmid DNA ratios, with the amount of pGAG kept constant
at 10 Ag. The assembly and processing of Gag particles was
analyzed by Western immunoblotting. The results shown in
Fig. 3 indicate that levels of Gag proteins in the medium
became reduced stepwise when the amount of wt or mutant
FS plasmid DNA used for cotransfection was increased.
Drastic reduction in the level of particle-associated Gag
was observed when 10 Ag plasmid DNA of each of the FS
constructs was used for cotransfection (lanes 1, 4, and 7). This
is consistent with the previous observation that cotransfection
with a higher amount of Gag-Pol expression plasmid DNA
could result in a significant reduction in Pr55gag particle
production (Chiu et al., 2002). The level of intracellular p24/
p25 produced byMA(p6*-PR)FSDwas comparable to that of
FS (lanes 10 and 13). However, the level of intracellular
processed Gag products in the MA(p6*-PR)FSD cotransfec-
tants was noticeably reduced or beyond the limit of detection
when the amount of the Gag-Pol expression plasmid DNA
used for cotransfection was reduced to 0.5–0.1 Ag (Fig. 3,
lanes 14 and 15). Conversely, both FS and MA(p6*-D25)FS
could still produce noticeable or detectable amounts of
intracellular p24/25gag when only 0.1 Ag of plasmid DNA
was used for cotransfections (lanes 12 and 18). This suggests
that the proteolytic activity of PR was affected somewhat
Fig. 3. Dose effects of chimeric PR expression plasmid DNA on Gag
particle assembly and processing. 293T cells were cotransfected with 10 Ag
of pGAG and the indicated amounts of designated plasmid DNA. The
amount of total DNA in each transfection was kept at 20 Ag by addition of
pBlueScript SK. At 48 h posttransfection, supernatants and cells were
collected, prepared, and subjected to Western immunoblot analysis as
described in the legend to Fig. 2. The positions of HIV Gag proteins Pr55,
p41, and p24 are indicated on the left.
Fig. 4. Effects of the p6*-PR blocking mutation on Gag particle assembly
and processing at different ratios of cotransfected plasmid DNA. 293T cells
were cotransfected with 10 Ag of pGAG plus the indicated amount of the
designated plasmid. Cells and supernatants were collected, prepared, and
analyzed by Western immunoblot as described in the legend to Fig. 3. HIV
Gag proteins Pr55, p41, and p24/25, and Gag-Pol precursor polyproteins
Pr160 are indicated on the left and the positions of the molecular size
markers (Std.) are shown on the right.
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impaired PR activity could be masked or compensated for by
overexpression of the PR through using a higher dose of
plasmid DNA. Intriguingly, the MA(p6*-D25)FS even pro-
duced a higher level of medium- and cell-associated p24gag
than the FS when only 0.1 Ag plasmid DNA was used for
cotransfection. These data suggest that the inactivated PR
domain inserted into the MA region did not significantly
affect the enzymatic activity of the downstream native PR and
that a minimum amount of PR is sufficient to provide enough
PR activity to process Gag particles.
The suppression effect of overexpressed Gag-Pol on virus
budding could be markedly alleviated by a blocking
mutation at p6*-PR
We have previously found that the budding defect caused
by the MA(p6*-PR) mutation could be rescued by suppress-
ing chimeric PR activity through inactivation of the PR viasubstitution mutation of the catalytic aspartic acid residue, or
through the addition of an HIV protease inhibitor (Wang et
al., 2000). Since cleavage of p6* from the PR is required for
the PR to be fully functional, we speculated that blocking the
N-terminal PR cleavage may attenuate the PR-mediated
premature Gag processing and lead to an increase in the level
of both virus particle budding and particle-associated Gag-
Pol. To test this possibility, the Phe residue at the p6*-PR
cleavage site (F/P) was replaced with a Val residue and the
resulting mutation (V/P) was introduced into the FS and
MA(p6*-PR)FSD, yielding (V/P)FS and MA(V/P-PR)FSD,
respectively (Fig. 1). Each of the FS constructs was used in
cotransfections with pGAG at various plasmid DNA ratios.
The effects of the mutation on virus particle processing and
budding were analyzed by Western immunoblotting. The
results shown in Fig. 4 indicate that the deleterious effect of
S.-W. Chen et al. / Virology 318 (2004) 534–541538higher PR expression on virus particle production was
somewhat diminished by the V/P mutation, as the MA(V/P-
PR)FSD and (V/P)FS produced markedly higher levels of
medium-associated Gag proteins than their wt counterparts
when used in transfections with pGAG at 10 Ag plasmid DNA
(lanes 5 and 7 vs. 3 and 1). However, mature particle-
associated p24gag was still barely detectable or was present
in the form of incompletely processed CA-p2 (p25gag). A
significant amount of medium p24/25gag doublet (lane 7)
indicates that the PR activity was somewhat affected by the
V/P mutation, which is consistent with a previous report
(Tessmer and Krausslich, 1998).
The incorporated chimeric Gag-Pol carrying an active PR in
the MA region was severely defective both in autoprocessing
and in Gag particle processing
The results shown in Fig. 4 indicate that particle-
associated mutant Pr160gag-pol precursor polyproteins couldFig. 5. Assembly and processing of HIV Gag proteins and virus-associated Pol pro
amount of the designated plasmid. At 48 h posttransfection, cells and culture super
of the supernatant samples was used undiluted and diluted twofold (1/2), and loade
plus p17gag monoclonal antibodies and a mouse anti-HIV-1-RT monoclonal antibo
associated Pol proteins Pr160gag-pol and p66/51 in each sample were quantified by
protein levels were calculated for each of the samples, and normalized to that of w
except that it was intentionally exposed longer. Band densities were taken from tbe detected by an anti-p24gag antibody (lanes 4–6). The
defect in particle processing by chimeric Gag-Pol may be
due to the inability of embedded PR to be functionally
active once incorporated into virus particles. Alternatively,
the PR may have been cleaved off Gag-Pol before the
Gag-Pol was incorporated into virus particles. To test these
possibilities and to quantify the particle-associated Gag-Pol
more precisely and specifically, supernatant samples from
cotransfections were serially diluted and analyzed by
Western immunoblotting using an anti-RT and anti-p24gag
together with anti-p17gag monoclonal antibodies. When 1
Ag of plasmid DNA was used for cotransfection with
pGAG, both FS and MA(p6*-D25)FS produced mature
p24gag and p17gag, which represented the major particle-
associated Gag species (Fig. 5, lanes 1–2 and 5–6).
Particle-associated RT proteins of both FS and MA(p6*-
D25)FS were present in mature heterodimer form p66/p51,
with no detectable Pr160gag-pol precursors (lanes 1–2 and
5–6). When normalized to medium Gag proteins, theteins. 293T cells were cotransfected with 10 Ag of pGAG plus the indicated
natants were collected and prepared for Western immunoblot analysis. Each
d in parallel. HIV Gag and Pol proteins were probed with mouse anti-p24gag
dy, respectively. Levels of HIV Gag proteins Pr55, p41, and p24/25, and RT-
scanning band densities on the immunoblot. Ratios of total Pol versus Gag
t FS in parallel experiments. The bottom panel is identical to the middle one
he middle panel.
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comparable to or even higher than that of wt FS. This
suggests that the Gag-Pol of MA(p6*-D25)FS was com-
petent both in autoprocessing and in trans processing of
Gag particles, and that the insertion of an inactivated PR in
the MA region has no major effects on the incorporation of
Gag-Pol into virus particles.
In contrast, the Pr160gag-pol precursor polyprotein was
the only product detected by the anti-RT antibody in either
MA(p6*-PR)FSD or MA(V/P-PR)FSD cotransfectant me-
dium samples (Fig. 5, lanes 4, 7, and 8) although precursor
and mature RT species could be detected in both of the
cotransfectants (data not shown). The level of particle-
associated mutant Gag-Pol was about 20–40% of that of
wt FS in independent repeat experiments. The Gag-Pol
protein levels were roughly compatible with their in vitro
RT activity levels in the serially diluted medium samples
(data not shown). This suggests that the embedded PR in
the incorporated Gag-Pol could not function properly. The
MA(p6*-PR)FSD exhibited a level of particle-associated
Gag-Pol that was relatively lower than that of MA(V/P-
PR)FSD, suggesting that the cleavage mutation V/P at the
embedded p6*-PR might have an overall positive effect on
the incorporation of Gag-Pol into virus particles, presum-
ably due to an increase in both virus budding and Gag-Pol
incorporation via suppression of the PR activity. In the
case of (V/P)FS, mature RT proteins with incompletely
processed Gag and Gag-Pol precursors were observed,
indicating that the PR in the incorporated Gag-Pol is not
fully functional (Fig. 5, lanes 9–10). Alternatively and/or
additionally, the level of Gag-Pol incorporated may be not
be sufficient to compensate for the negative effect of the V/
P mutation on PR activity. When 10 Ag of (V/P)FS
plasmid DNA was used for cotransfection, significant
amounts of mature Gag and RT proteins were detected in
the medium (lane 11). This suggests that a higher expres-
sion level of Gag-Pol could overcome the negative effects
of the V/P mutation on Gag-Pol incorporation and particle
processing.Discussion
We have shown that the MA(p6*-PR)FSD carrying an
active HIV-1 PR in the MA region displayed a steady-state
intracellular Gag processing profile similar to that of FS
when coexpressed with equivalent amounts of Pr55gag-
expression plasmid DNA in 293T cells. Compared to the
FS, however, the MA(p6*-PR)FSD produced a relatively
lower level of intracellular p24/25gag when used in cotrans-
fections with pGAG at a DNA ratio of 1:20 to 1:100. These
results suggest that positioning the HIV-1 PR in the MA
region may have impaired the process of PR activation
somewhat. Since dimerization of PR is a prerequisite for
PR activation and sequences outside the PR domain have
been proposed to be involved in the process of PRdimerization (Pettit et al., 2003; Quillent et al., 1996;
Zybarth and Carter, 1995), repositioning the PR out of its
native position may have disturbed the process of PR
dimerization substantially. Although it is unknown whether
the downstream inactivated PR domain could affect the
activation of chimeric PR, removal of the pol coding
sequence from the MA(p6*-PR)FSD showed no major
effects on the steady-state processing of Pr55gag (data not
shown). Further experiments are required to study the
kinetic activity of the chimeric PR.
The Gag-Pol precursor polyproteins containing an em-
bedded PR in the MA region could be readily detected by
using an anti-p24gag or anti-RT monoclonal antibody. Since
a minimal amount of particle-associated Gag-Pol is suffi-
cient to cleave Pr55gag to produce readily detectable p24gag
in the medium, the absence of particle-associated p24gag in
the cotransfectant medium may suggest that intraviral Gag
processing by the incorporated chimeric PR was markedly
impaired. However, we cannot exclude the possibility that
the activated PR may have been cleaved off the Gag-Pol
before the Gag-Pol was incorporated into virus particles.
Nevertheless, partial cleavage of intraviral Pr55gag did occur
at some of the cleavage sites, as intermediate p41gag and the
incompletely cleaved p25gag were readily detected. It is not
entirely clear how the cleavage sites at Pr55gag are sequen-
tially cleaved by the PR. In vitro studies of the ordered
cleavage of Gag have suggested that MA/CA is cleaved at a
rate that is about 10-fold lower than cleavage of p2/NC,
which is cleaved first during Gag processing, while the rate
of cleavage at CA/p2 is extremely slow, about 400-fold
lower than that of p2/NC (Erickson-Viitanen et al., 1989;
Krausslich et al., 1989; Pettit et al., 2003). The ability of the
MA(p6*-PR)FSD to undergo autoprocessing and to prevent
Gag virus particle production when a higher dose of plasmid
DNAwas used for cotransfection suggests that the chimeric
PR could form activated PR dimer to cleave the scissile
bonds. It is conceivable that a higher expression level of PR
may promote the dimerization of PR for subsequent PR
activation. Thus, the overexpression of MA(p6*-PR)FSD
could still block virus budding by premature processing of
Pr55gag although its encoded PR may possess less enzy-
matic activity than that of FS.
Despite being competent in trans processing of intracel-
lular Pr55gag, the embedded PR in the MA region was
severely defective both in the proteolytic processing of Gag-
Pol and Gag particles once the chimeric Gag-Pol was
incorporated into virus particles. One possibility is that the
intracellular Gag-Pol could be more flexible and tend to
adopt a conformation that allows the process of PR dimer-
ization to proceed. In contrast, the framework of virus
particle may be relatively rigid, which might hamper the
process of PR activation and/or prevent the embedded PR
from gaining access to the cleavage sites. In conclusion, our
results suggest that the process of HIV PR-mediated Gag
particle processing is affected significantly when the PR is
placed out of its native position.
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Plasmid construction
An HIV replication-defective expression vector, HIVgpt
(Page et al., 1990), was used to express Gag and Gag-Pol.
All the other Pr55gag and/or Pr160gag-pol expression con-
structs were derived from HIVgpt. D25, a PR-defective
version of HIVgpt, containing a substitution of an Arg
residue for the catalytic residue Asp (Wang et al., 2000).
The pGAG was constructed by deletion of most of the pol
sequence from BclI-2429 to SalI-5786, and the Pr160gag-pol-
expression plasmid, FS, was engineered by deletion of five
T nucleotides in the gag and pol junction as described
previously (Chiu et al., 2002). For construction of plasmid
V/P, the amino acid residues at the p6*-PR cleavage site of
HIVgpt were changed from Phe/Pro to Val/Pro (V/P) by
PCR-mediated mutagenesis. To make constructs MA(p6*-
PR), MA(p6*-D25), and MA(V/P-PR), PCR-generated
fragments p6*-PR from templates HIVgpt, D25, and V/P
were amplified by PCR, treated with ClaI and SalI and used
to replace the fragment ClaI-831 to SalI-1147 in an HIV gag
mutant carrying a SalI linker at nt 1147 (Wang and Barklis,
1993). The primer sequences for amplifying the p6*-PR
fragment were 5V-CTTCCATCGATGGAAGGCCA-3V and
5V-TACTGGTCGACTCTCAATAGGGCT-3V. Recombination
of the resulting mutants with FS or with a PR-defective
version of FS (FSD) yielded constructs MA(p6*-PR)FSD,
MA(p6*-D25)FS, and MA(V/P-PR)FSD. Each mutant con-
struct was confirmed either by restriction enzyme digestion
or by DNA sequencing.
Cell culture and transfection
293T cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (GIBCO). Twenty-four hours before transfection,
confluent 293T cells were trypsinized, split 1:10, and
seeded onto 10-cm dishes. Twenty micrograms of WT or
mutant HIVgpt plasmid DNA was used to transfect 293T
cells using the calcium phosphate precipitation method,
with addition of 50 AM chloroquine to enhance the trans-
fection efficiency. When pGAG was used in cotransfections
with the Pr160gag-pol-expression constructs at a variety of
DNA ratios, 10 Ag of pGAG plasmid DNA was used with
the addition of pBlueScript plasmid DNA to a final quantity
of 20 Ag DNA. The cells and media were harvested for
protein analysis 48–72 h posttransfection.
Protein analysis
Two to 3 days after transfection, culture supernatants
were collected, filtered through 0.45 Am-pore-size syringe
filters, and centrifuged for 40 min at 274,000  g (SW41
rotor at 40,000 rpm) through 2 ml 20% sucrose in TSE (10
mM Tris–HCl [pH 7.5], 100 mM NaCl, 1 mM EDTA, and0.1 mM phenylmethylsulfonyl fluoride [PMSF]) at 4 jC.
The cells were rinsed twice with ice-cold phosphate-buff-
ered saline (PBS), collected in 1 ml PBS, and spun at 3000
rpm for 5 min. Viral and cell pellets were suspended in
IPB buffer (20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1
mM EDTA, 0.1% SDS, 0.5 sodium deoxycholate, 1% Triton
X-100, 0.02% sodium azide) containing 0.1 mM PMSF. Cell
lysates were microcentrifuged at 4 jC for 15 min at 13,700
g (14,000 rpm) to remove cell debris. The supernatant
and cell samples were prepared and subjected to 10%
polyacrylamide gel electrophoresis (PAGE) as previously
described (Wang et al., 1998). Membrane-bound HIV
proteins were immunodetected by a colorimetric method
or by an enhanced chemiluminescence (ECL) detection
system. For detection of HIV Gag proteins, the primary
antibody was an anti-p24gag (hybridoma clone 183-H12-
5C) or anti-p17gag (Chiu et al., 2002) monoclonal antibody
from ascites used at a 1:5000 dilution. An anti-HIV-1 RT
monoclonal antibody (5011, Biotechnology Transfer, Co-
lumbia, MD) diluted 1:1000 was used to detect the HIV
RT. The secondary antibody was either a horse anti-mouse
IgG alkaline phosphatase-conjugated antibody (Vector Lab-
oratories, Burlingame, CA) or a sheep anti-mouse horse-
radish peroxidase (HRP)-conjugated antibody diluted
1:5000. Alkaline phosphatase activity was detected by
placing the blots in color reaction solution containing
NBT and BCIP (Promega). Procedures for HRP activity
detection followed the manufacturer’s protocol (Amersham,
Arlington Heights, IL). Immunodetected bands on the films
were quantified with a Personal Densitometer (Molecular
Dynamics, Sunnyvale, CA).
In vitro RT assay
The culture medium of transfected cells was harvested,
filtered, and pelleted as described above. Pellets were
suspended in TSE and aliquots were taken for protein
analysis and RT assay. To optimize RT assay conditions
and to keep the detected RT activity linear with the sample
concentration, viral pellets in TSE were serially diluted.
Ten-microliter aliquots of each sample were mixed with 40
Al reaction cocktail containing 0.1% Triton X-100, 5 mM
DTT, 10 mM MgCl2, 50 mM Tris–HCl [pH 8.0], 1.2 mM
poly(rA)-(dT)15, and 25 ACi of [3H]TTP per milliliter (Wang
et al., 1998). After incubation at 37 jC for 2 h, 5 Al tRNA
(10 mg/ml) was added to the reaction mixture, precipitated
with ice-cold 10% trichloroacetic acid (TCA) and filtered
using GF/C membranes. The filters then were washed twice
with 5% TCA, dried, and counted in a Beckman scintillation
counter for determination of RT activity.Acknowledgments
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